208 related articles for article (PubMed ID: 15959831)
21. Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors.
Izenwasser S; Acri JB; Kunko PM; Shippenberg T
Synapse; 1998 Nov; 30(3):275-83. PubMed ID: 9776131
[TBL] [Abstract][Full Text] [Related]
22. An evaluation of l-ephedrine neurotoxicity with respect to hyperthermia and caudate/putamen microdialysate levels of ephedrine, dopamine, serotonin, and glutamate.
Bowyer JF; Newport GD; Slikker W; Gough B; Ferguson SA; Tor-Agbidye J
Toxicol Sci; 2000 May; 55(1):133-42. PubMed ID: 10788568
[TBL] [Abstract][Full Text] [Related]
23. Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment.
Cappon GD; Pu C; Vorhees CV
Brain Res; 2000 Apr; 863(1-2):106-11. PubMed ID: 10773198
[TBL] [Abstract][Full Text] [Related]
24. Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences.
Davidson C; Lee TH; Ellinwood EH
Neurochem Int; 2005 Feb; 46(3):189-203. PubMed ID: 15670635
[TBL] [Abstract][Full Text] [Related]
25. Parallel development of dopamine metabolism tolerance in the rat prefrontal cortex, caudate-putamen, and amygdala following haloperidol decanoate administration.
Kurachi M; Shibata R; Murata M; Tanii Y
Biol Psychiatry; 1995 Apr; 37(7):487-90. PubMed ID: 7786966
[No Abstract] [Full Text] [Related]
26. Caudate-putamen and nucleus accumbens extracellular acetylcholine responses to methamphetamine binges.
Kuczenski R; Segal DS
Brain Res; 2001 Dec; 923(1-2):32-8. PubMed ID: 11743969
[TBL] [Abstract][Full Text] [Related]
27. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.
Volkow ND; Chang L; Wang GJ; Fowler JS; Leonido-Yee M; Franceschi D; Sedler MJ; Gatley SJ; Hitzemann R; Ding YS; Logan J; Wong C; Miller EN
Am J Psychiatry; 2001 Mar; 158(3):377-82. PubMed ID: 11229977
[TBL] [Abstract][Full Text] [Related]
28. Repeated exposure to the herbicide atrazine alters locomotor activity and the nigrostriatal dopaminergic system of the albino rat.
Rodríguez VM; Limón-Pacheco JH; Mendoza-Trejo MS; González-Gallardo A; Hernández-Plata I; Giordano M
Neurotoxicology; 2013 Jan; 34():82-94. PubMed ID: 23123945
[TBL] [Abstract][Full Text] [Related]
29. Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum.
Theodore S; Cass WA; Maragos WF
Neuroscience; 2006 Feb; 137(3):925-35. PubMed ID: 16338084
[TBL] [Abstract][Full Text] [Related]
30. Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat.
Shepard JD; Chuang DT; Shaham Y; Morales M
Psychopharmacology (Berl); 2006 May; 185(4):505-13. PubMed ID: 16555063
[TBL] [Abstract][Full Text] [Related]
31. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.
Heidbreder CA; Schenk S; Partridge B; Shippenberg TS
Synapse; 1998 Nov; 30(3):255-62. PubMed ID: 9776129
[TBL] [Abstract][Full Text] [Related]
32. Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.
McFadden LM; Vieira-Brock PL; Hanson GR; Fleckenstein AE
Neuropharmacology; 2015 Jun; 93():146-54. PubMed ID: 25645392
[TBL] [Abstract][Full Text] [Related]
33. Escalating dose-binge stimulant exposure: relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses.
Segal DS; Kuczenski R
Psychopharmacology (Berl); 1999 Feb; 142(2):182-92. PubMed ID: 10102771
[TBL] [Abstract][Full Text] [Related]
34. Effects on precise motor responding of bilateral intrastriatal application of dopamine.
Butcher LL; Gan J
Behav Biol; 1974 Dec; 12(4):533-9. PubMed ID: 4476209
[No Abstract] [Full Text] [Related]
35. Methamphetamine exposure during the preweanling period causes prolonged changes in dorsal striatal protein kinase A activity, dopamine D2-like binding sites, and dopamine content.
Crawford CA; Williams MT; Newman ER; McDougall SA; Vorhees CV
Synapse; 2003 Jun; 48(3):131-7. PubMed ID: 12645038
[TBL] [Abstract][Full Text] [Related]
36. Exposure of mice to tobacco smoke attenuates the toxic effect of methamphetamine on dopamine systems.
Bondy SC; Ali SF; Kleinman MT
Toxicol Lett; 2000 Dec; 118(1-2):43-6. PubMed ID: 11137307
[TBL] [Abstract][Full Text] [Related]
37. Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles.
Melega WP; Jorgensen MJ; Laćan G; Way BM; Pham J; Morton G; Cho AK; Fairbanks LA
Neuropsychopharmacology; 2008 May; 33(6):1441-52. PubMed ID: 17625500
[TBL] [Abstract][Full Text] [Related]
38. Deprenyl treatment attenuates long-term pre- and post-synaptic changes evoked by chronic methamphetamine.
Davidson C; Chen Q; Zhang X; Xiong X; Lazarus C; Lee TH; Ellinwood EH
Eur J Pharmacol; 2007 Nov; 573(1-3):100-10. PubMed ID: 17651730
[TBL] [Abstract][Full Text] [Related]
39. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.
Volkow ND; Chang L; Wang GJ; Fowler JS; Franceschi D; Sedler M; Gatley SJ; Miller E; Hitzemann R; Ding YS; Logan J
J Neurosci; 2001 Dec; 21(23):9414-8. PubMed ID: 11717374
[TBL] [Abstract][Full Text] [Related]
40. Sensitization of amphetamine-induced stereotyped behaviors during the acute response.
Kuczenski R; Segal DS
J Pharmacol Exp Ther; 1999 Feb; 288(2):699-709. PubMed ID: 9918578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
